TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01977859

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nesiritide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nesiritide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nesiritide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nesiritide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT02549833

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBM6-AD and poly-ICLC before and after surgery
Description: Subcutaneous vaccination with GBM6-AD lysate protein and poly-ICLC combination

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GBM6-AD and poly-ICLC after surgery only
Description: Subcutaneous vaccination with GBM6-AD lysate protein and poly-ICLC combination
Study: NCT03283670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide 50%
Description: Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at a concentration of 50% nitrous oxide/50% oxygen.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gas
Description: Placebo gas given at 50% nitrogen \[inert\]/50% oxygen.
Study: NCT00417859

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty: mobile bearing
Description: Total knee arthroplasty: mobile bearing
Study: NCT04040907

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XNW3009
Description: XNW3009 is a small molecule hURAT1 inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo and active drug will have the same appearance
Study: NCT03343145

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Leucostim 5µg/kg/day
Description: 5µg/kg/day (based on actual body weight) Leucostim®, subcutaneously, once a day, for up to 14 days or until the target ANC of 10,000/mm3 following the expected chemotherapy-induced ANC nadir

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Neupogen 5µg/kg/day
Description: 5µg/kg/day (based on actual body weight) Neupogen®, subcutaneously, once a day, for up to 14 days or until the target ANC of 10,000/mm3 following the expected chemotherapy-induced ANC nadir
Study: NCT02793375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Age appropriate dose of Montelukast given to patients prior to undergoing adenotonsillectomy, and the day after surgery, with pain scores and amount of opioid pain medication required measured postoperatively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Age appropriate dose of placebo given to patients prior to undergoing adenotonsillectomy, and the day after surgery, with pain scores and amount of opioid pain medication required measured postoperatively.
Study: NCT01506570

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TetraVax-DV Vaccine - Admixture TV003
Description: One SC injection at Day 0 and Day 180 of the TetraVax-DV Vaccine, Admixture TV003 (10\^3 plaque-forming unit \[PFU\] of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30\[ME\], 10\^3 PFU of rDEN3Δ30/31-7164, and 10\^3 PFU of rDEN4Δ30)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TetraVax-DV Vaccine - Admixture TV005
Description: One SC injection at Day 0 and Day 180 of the TetraVax-DV Vaccine, Admixture TV005 (10\^3 PFU of rDEN1Δ30, 10\^4 PFU of rDEN2/4Δ30\[ME\], 10\^3 PFU of rDEN3Δ30/31-7164, and 10\^3 PFU of rDEN4Δ30)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One SC injection at Day 0 and Day 180 of placebo
Study: NCT04596566

Intervention type: OTHER
Group type: OTHER
Intervention: Therapeutic diet Intervention
Description: The CD-TDI will incorporate global principles of the Mediterranean Diet (MD) refined to inform specific food choices based on our pilot data results and published literature reported mechanisms of mitigating inflammation in IBD. Patient compliance will be measured in three ways: 1) Mediterranean diet score checklists completed every 3 weeks at the face-to-face visits; 2) goal attainment scores captured weekly to identify the goals set, and the goals attained 47; and 3) fatty acids profiled from red blood cells to identify if fat intake reflects CD-TDI fat recommendations: 35% total calories from fat, 15% from MUFA, 13% from SFA and 6% from PUFA with a 8 n6:n:3 ratio of 8:1
Study: NCT04446663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab 240mg ivdrip, every 3 weeks for 6 cycles, with 3 cycles combined with induction chemotherapy, 3 cycles combined with concurrent chemoradiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-bound Paclitaxel
Description: Albumin-bound Paclitaxel 260 mg/m2, d1 of every cycle, every 3 weeks for 3 cycles before radiotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin-bound Paclitaxel
Description: Albumin-bound Paclitaxel 260 mg/m2, d1 of every cycle, every 3 weeks for 3 cycles before radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiotherapy Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiotherapy Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiotherapy
Description: Definitive IMRT of ≥66 Gy will be given .

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: intensity-modulated radiotherapy
Description: Definitive IMRT of ≥66 Gy will be given .
Study: NCT02394743

Intervention type: RADIATION
Intervention: 18FDG-PET

Intervention type: RADIATION
Intervention: 18FDG-PET
Study: NCT00963105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Depending on the starting dose, subjects will be allocated in a double-blind fashion to three different regimens and will escalate every 28 days, based on individual subject tolerability, as follows:~* Treatment Arm 1: 5 mg →10 mg →15 mg →20 mg →25 mg/daily~* Treatment Arm 2: 10 mg →15 mg →20 mg →25 mg/daily~* Treatment Arm 3: 15 mg →20 mg →25 mg/daily Subjects will continue treatment until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Depending on the starting dose, subjects will be allocated in a double-blind fashion to three different regimens and will escalate every 28 days, based on individual subject tolerability, as follows:~* Treatment Arm 1: 5 mg →10 mg →15 mg →20 mg →25 mg/daily~* Treatment Arm 2: 10 mg →15 mg →20 mg →25 mg/daily~* Treatment Arm 3: 15 mg →20 mg →25 mg/daily Subjects will continue treatment until disease progression or unacceptable toxicity
Study: NCT03181633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACH-0144471
Description: ACH-0144471 will be administered to all participants enrolled in the study.
Study: NCT02743624

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Variation of the level of pressure support during the mechanical ventilation
Description: The pressure support of the patient was changed form the baseline to 20 cmH20 and then stepwise decreased to 2 cmH20,
Study: NCT02254382

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive servo ventilation (ASV)
Description: Non-invasive Ventilation used to control central and obstructive sleep apnea.
Study: NCT03519412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide (induction),
Description: temozolomide is administered to MGMT promoter methylation-positive MMRp patients orally, once daily, at the dose of 150-200 mg/m2/day for 5 consecutive days of each treatment cycle A treatment cycle will comprise 5 days of temozolomide administration (Day 1 to 5) followed by 23 days of rest for a total of 28 days (4 weeks) period (dose-schedule: 150 mg/m2 day 1-5 q28),until disease progression or unacceptable toxicity whichever comes first.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: pembrolizumab (treatment)
Description: pembrolizumab is administered to MGMT-IHC-negative, MGMT promoter methylation-positive MMRp patients with TMB\>20 Mut/Mb after Temozolomide treatment, and to MMRd. Patients receive pembrolizumab IV , 200 mg Q3W, Day 1 of each 3 week cycle for maximum 35 cycles, until disease progression or unacceptable toxicity whichever comes first.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab (treatment)
Description: pembrolizumab is administered to MGMT-IHC-negative, MGMT promoter methylation-positive MMRp patients with TMB\>20 Mut/Mb after Temozolomide treatment, and to MMRd. Patients receive pembrolizumab IV , 200 mg Q3W, Day 1 of each 3 week cycle for maximum 35 cycles, until disease progression or unacceptable toxicity whichever comes first.
Study: NCT01313897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: bortezomib to be given days -9, -6, and -2 at 1.0mg/m2, i.v.
Study: NCT02542007

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrbusNeich Combo stent™
Description: The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sirolimus-eluting stent system
Study: NCT02342678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Conditioning
Study: NCT03113812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABvac40

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00359424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV rt-PA alone
Description: Intravenous (IV) recombinant tissue plasminogen activator (rt-PA) is the only approved acute stroke therapy; Group one will receive the standard dose of IV rt-PA given over an hour.
Study: NCT02394743

Intervention type: RADIATION
Intervention: 18FDG-PET
Study: NCT03774641

Intervention type: DRUG
Intervention: Lamictal
Description: Blood-serum levels will be checked monthly during pregnancy and reference concentration will be maintained
Study: NCT01847508

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PHILOS+
Description: Proximal Humerus Internal Locking System with screw tip augmentation (PHILOS+) with high viscous polymethylmethacrylate (PMMA) cement (Traumacem V+).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PHILOS
Description: Proximal Humerus Internal Locking System (PHILOS).
Study: NCT04064281

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the healthy Cantonese diet
Description: After a 1-week run-in period, the intervention group will eat the healthy Cantonese diet for 4 consecutive weeks. Free meals will be provided 3 times a day (breakfast, lunch, dinner). The actually intake of every meal for all subjects will be recorded to estimate their nutrients intake. All subjects will be advised to avoid eating other food, but they should inform researchers of what they eat if they eat food that we will not provide.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: the typical Cantonese diet
Description: After a 1-week run-in period, the control group will still eat the typical Cantonese diet for 4 consecutive weeks. Free meals will be provided 3 times a day (breakfast, lunch, dinner). The actually intake of every meal for all subjects will be recorded to estimate their nutrients intake. All subjects will be advised to avoid eating other food, but they should inform researchers of what they eat if they eat food that we will not provide.
Study: NCT03937167

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychotherapy group
Description: Added to standard treatment patients will participate in a standardized group of psychological intervention. 21 sessions with 10 to 12 members closed-ended groups.
Study: NCT02663817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT Scan
Study: NCT01471002

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Galil Medical patented 17G Cryoablation Needles
Study: NCT02775383

Intervention type: OTHER
Intervention: Therapeutic
Description: Observational Study

Intervention type: OTHER
Intervention: Therapeutic
Description: Observational Study
Study: NCT02389543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Two different dosing schedules will be tested, once weekly and twice weekly. If the selinexor 80 mg dose is tolerated, the dose will be increased to 100 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Two different dosing schedules will be tested, once weekly and twice weekly. If the selinexor 80 mg dose is tolerated, the dose will be increased to 100 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: In both arms, lenalidomide will be started at 15 mg/day (Dose Level 1) and, if tolerated per DLT criteria, will be escalated to 25 mg/day (Dose Level 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: In both arms, lenalidomide will be started at 15 mg/day (Dose Level 1) and, if tolerated per DLT criteria, will be escalated to 25 mg/day (Dose Level 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be given in combination with each dose of selinexor on the once weekly treatment arm.~For the twice weekly arm dexamethasone will be given in combination with each dose of selinexor and will also be given without selinexor on Days 22 and 24.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be given in combination with each dose of selinexor on the once weekly treatment arm.~For the twice weekly arm dexamethasone will be given in combination with each dose of selinexor and will also be given without selinexor on Days 22 and 24.
Study: NCT02252055

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATDC_Nantes
Description: ATDC treatment (1 x 106 cells/kg BW slow peripheral venous) occurs the day before transplantation into recipients also recipients of a living donor renal transplantation.~Recipients also receive prednisolone, Mycophenolate Mofetil and tacrolimus background immunosuppression ( as described in detail in the arm description)
Study: NCT03431168

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin/TMPS
Description: 2 tabs po daily x 3 days at enrollment and at each monthly follow up visit

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/TMPS
Description: 2 tabs po daily x 3 days at enrollment and at each monthly follow up visit
Study: NCT00809757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levalbuterol
Description: 90 ug Levalbuterol (2 actuations)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levalbuterol UDV TID
Description: 0.31 ug Levalbuterol UDV TID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (2 actuations)
Study: NCT00924950

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taclonex Ointment and Hydrogel Patch
Description: Each patient will have bilateral symmetrical psoriatic plaques. One plaque will be treated with Taclonex Ointment daily along with Hydrogel Patch daily. All treatment will be for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taclonex Ointment
Description: Taclonex ointment daily for one psoriatic plaque.
Study: NCT01053858

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intravitreal injection
Description: intravitreal bevacizumab( 1.25 mg) or triamcinolone( 4mg) injection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intravitreal injection
Description: intravitreal bevacizumab( 1.25 mg) or triamcinolone( 4mg) injection
Study: NCT04121728

Intervention type: DRUG
Group type: OTHER
Intervention: Ginkgo biloba extract
Description: Symfona® commercial standardized Ginkgo biloba extracts are used in this study, at a rate of 2 capsules of 120 mg per day for 170 days.

Intervention type: DRUG
Group type: OTHER
Intervention: Ginkgo biloba extract
Description: Symfona® commercial standardized Ginkgo biloba extracts are used in this study, at a rate of 2 capsules of 120 mg per day for 170 days.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: The placebo is presented in the form of capsules of identical mass, color and shape to those of the study product. It is composed of lactose, the excipients present in Symfona® 120 mg and colorants. The dosage is identical to that of the investigational product.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: The placebo is presented in the form of capsules of identical mass, color and shape to those of the study product. It is composed of lactose, the excipients present in Symfona® 120 mg and colorants. The dosage is identical to that of the investigational product.
Study: NCT00557115

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early pulmonary rehabilitation (EPR)
Description: Multidisciplinary exercise programme in the format of standard pulmonary rehabilitation. Consists of 2 supervised exercise and educations sessions per week for up to 16 sessions within 3-months. Participants are encouraged to keep an exercise diary at perform at least one exercise session at home unsupervised.
Study: NCT00963105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Depending on the starting dose, subjects will be allocated in a double-blind fashion to three different regimens and will escalate every 28 days, based on individual subject tolerability, as follows:~* Treatment Arm 1: 5 mg →10 mg →15 mg →20 mg →25 mg/daily~* Treatment Arm 2: 10 mg →15 mg →20 mg →25 mg/daily~* Treatment Arm 3: 15 mg →20 mg →25 mg/daily Subjects will continue treatment until disease progression or unacceptable toxicity
Study: NCT00610194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA119
Description: In the dose escalation phase, subjects will receive a single oral dose of RDEA119 on Day 1, wait 1 week, then begin a 28-day course of daily continuous dosing of RDEA119. In the expanded MTD phase, subjects will receive RDEA119 once or twice a day beginning on Day 1, and begin a 28-day course of continuous dosing at that time.
Study: NCT01233089

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B contact lens, investigational
Description: Investigational silicone hydrogel, spherical contact lens worn on a daily wear basis and replaced monthly

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lotrafilcon B contact lens, commercial (AIR OPTIX AQUA)
Description: Commercially available silicone hydrogel, spherical contact lens worn on a daily wear basis and replaced monthly.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lotrafilcon B multifocal contact lens, commercial (AIR OPTIX AQUA MULTIFOCAL)
Description: Commercially available silicone hydrogel, multifocal, contact lens worn on a daily wear basis and replaced monthly.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contact lens care system (ClearCare)
Description: Commercially available, hydrogen peroxide-based system for cleaning, disinfecting, and storing contact lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contact lens care system (ClearCare)
Description: Commercially available, hydrogen peroxide-based system for cleaning, disinfecting, and storing contact lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact lens care system (ClearCare)
Description: Commercially available, hydrogen peroxide-based system for cleaning, disinfecting, and storing contact lenses
Study: NCT04364035

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1.HTI
Description: ChAdOx1.HTI at week 0 and week 12; Vaccine delivered as one 0. 5 mL IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.HTI
Description: MVA.HTI at week 24 and week 36; Vaccine delivered as one 0. 5 mL IM injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9620
Description: GS-9620 at week 26,28,30,32,34,38,40,42,44 and 46 Unit-dose tablet, delivered as two 3-mg tablets
Study: NCT00950001

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo SRS
Study: NCT03047031

Intervention type: DRUG
Intervention: Nintedanib
Description: Nintedanib

Intervention type: DRUG
Intervention: Pirfenidone
Description: Pirfenidone

Intervention type: DRUG
Intervention: Pirfenidone
Description: Pirfenidone
Study: NCT03343054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: talazoparib
Description: Talazoparib will be administered orally on a continuous basis. Talazoparib may be taken with or without food. Each cycle will consist of 28 days.
Study: NCT03169660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vascular endothelial growth factor trap-eye
Description: Intravitreal injection of vascular endothelial growth factor trap-eye During the first 3 months, 3 monthly injections are performed After 3 serial injections, additional injections are performed once per 2 months until 48 weeks after the initial injection.
Study: NCT04331418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 1 mcg/kg IV over 10 minutes followed by 0.5 mcg/kg/hr

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: caudal block
Description: After negative aspiration of blood or cerebrospinal fluid, 2 mg/ kg of bupivacaine at concentration of 0.5% (volume 0.5ml/kg) was given as per the group assigned, then the site of injection was dressed, and the patient was turned supine.
Study: NCT01614808

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03111407

Intervention type: PROCEDURE
Group type: OTHER
Intervention: total knee arthroplasty
Description: surgical procedure in which damaged parts of the knee joint are replaced with an implant.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: total knee arthroplasty
Description: surgical procedure in which damaged parts of the knee joint are replaced with an implant.
Study: NCT04639739

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19 CAR NK
Description: 2×106 /kg、6×106 /kg、2×107/kg Treatment follows a lymphodepletion, the recommended chemotherapy regimen consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (500mg/m2 per day) for 3 days prior to cell infusion，the actual regiment is determined by the statue of patients.
Study: NCT04615286

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short course (2-3 weeks) of antibiotics
Description: Shorter course of antibiotic than standard care of 4-6 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard (long course) of antibiotics
Description: 4-6 weeks of antibiotics